Uzay, A. 2020. BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE. 25th Congress of the European Hematology Association , (Frankfurt, Germany), 1-2.

Uzay, A., (2020). BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE . 25th Congress of the European Hematology Association (pp.1-2). Frankfurt, Germany

Uzay, Ant. "BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE," 25th Congress of the European Hematology Association , Frankfurt, Germany, 2020

Uzay, Ant. "BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE." 25th Congress of the European Hematology Association , Frankfurt, Germany, pp.1-2, 2020

Uzay, A. (2020) . "BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE." 25th Congress of the European Hematology Association , Frankfurt, Germany, pp.1-2.

@conferencepaper{conferencepaper, author={Ant UZAY}, title={BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELLTRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE}, congress name={25th Congress of the European Hematology Association }, city={Frankfurt}, country={Germany}, year={2020}, pages={1-2} }